Abstract: A method and composition for treating a Hepatitis B patient having hepatic decompensation utilizes Hepatitis B virus-reducing amounts of T.alpha..sub.1, administered to a patient having decompensated liver disease so as to render the patient seronegative for Hepatitis B virus DNA.
Type:
Grant
Filed:
September 26, 1996
Date of Patent:
May 12, 1998
Assignees:
Alpha 1 Biomedicals, Inc., The Board of Governors of Wayne State Univ.
Abstract: A method of promoting bone formation in a human patient, which includes the step of administering continuously to the patient parathyroid hormone or its agonist for a period of at least one month at a dosage between 10 and 400 units/24 hrs. Also disclosed are novel parathyroid hormone agonists.
Abstract: The present invention relates generally to methods and compositions for inhibiting wound contraction and the scarring that frequently results from such contraction. More particularly, the invention relates to the use of a protein tyrosine phosphatase inhibitor to block the dephosphorylation of protein tyrosine phosphatase receptors and interrupt the cyclic nature of wound contraction.
Type:
Grant
Filed:
October 31, 1995
Date of Patent:
April 21, 1998
Assignee:
Board of Regents, The University of Texas System
Abstract: A method is disclosed that comprises administering insulin-like growth factor-I (IGF-I) to a mammal so as to sustain its biological activity in the mammal comprising administering a therapeutically effective amount of IGF-I to the mammal to provide an exposure to IGF-I for a period of time that stimulates the maximum biological response in the mammal, then discontinuing said administration for a period of time equal to or less than the time period used for administration, and repeating this pattern of administration and discontinuance of administration for a period as long as necessary to achieve or maintain the desired biological response in the mammal.
Type:
Grant
Filed:
May 22, 1995
Date of Patent:
April 21, 1998
Assignees:
Genentech, Inc., Washington University
Inventors:
Ross G. Clark, Neil Gesundheit, Marc R. Hammerman, Steven B. Miller
Abstract: A method for treatment of a patient for obtaining an increased concentration of a factor selected from the group consisting of growth hormone, insulin-like growth factor (IGF-I) and IGFBP-3 in cerebrospinal fluid by administration of growth hormone or analogues thereof to a patient in need of said treatment.
Type:
Grant
Filed:
May 17, 1996
Date of Patent:
April 7, 1998
Assignee:
Pharmacia & Upjohn Aktiebolag
Inventors:
Bengt-.ANG.ke Bengtsson, Olle G. P. Isaksson, Jan-Ove Johansson
Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin and a water-soluble salt of calcium and/or magnesium.
Abstract: The present invention relates generally to methods for treating injury or degeneration of basal forebrain cholinergic neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating Alzheimer's disease.
Abstract: A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertebrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
February 10, 1998
Assignee:
Louisiana State University and Agricultural and Mechanical College
Abstract: A process for the long term modification and regulation of lipid metabolism--generally to reduce obesity, insulin resistance, and hyperinsulinemia (the three hallmarks of Type II diabetes)--by injections into the bloodstream of a vertabrate, animal or human, of prolactin, or both prolactin and a glucocorticosteroid. The injections are made over a limited period at a time of day dependent on the normal circadian rhythm of fat and lean members of a similar species. Decreases (or increases) in body fat deposits result by treatment of an obese species (lean species) on a daily timed sequence based on circadian rhythms of the peak prolactin, or peak prolactin and peak glucocorticosteroid, blood level established for lean members (or obese members) of a similar species. Insulin resistance, and hyperinsulinemia can also be controlled in humans on a long term basis by treatment corresponding to that of the treatment for obesity.
Type:
Grant
Filed:
May 26, 1995
Date of Patent:
February 10, 1998
Assignee:
Louisiana State University and Agricultural and Mechanical College
Abstract: Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R.sub.4, and R.sub.8 are each independently methyl or ethyl; R.sub.3 is preferably iso-butyl or phenyl; R.sub.5 is preferably iso-butyl; R.sub.6 is H or methyl; R.sub.7 --(Q).sub.n is preferably benzyloxycarbonyl or acetyl; Q is preferably --C(O)--; R.sub.8 is preferbly iso-butyl; R.sub.A =--(T).sub.m --(D).sub.m --R.sub.1, is which T is preferably oxygen or carbon, and D is preferably a mono-unsaturated C.sub.3-4 alkenyl being more preferred; and X is preferably an .alpha.-ketoester or .alpha.-ketoamide.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
February 3, 1998
Assignee:
SIBIA Neurosciences, Inc.
Inventors:
Blake Alan Rowe, Robert Steven Siegel, Steven Lee Wagner
Abstract: A method of treating prostate cancer in warm-blooded animals comprising administering to warm-blooded animals an effective amount of a peptide of Formula I and an anti-androgen.
Abstract: The present invention relates to a composition comprising exogenous human or animal IGF-I or IGF-II or both or effective analogs thereof comprising foodstuff for oral administration wherein the foodstuff is selected from the group consisting of artificial milk, natural milk and colostrum.
Type:
Grant
Filed:
March 7, 1996
Date of Patent:
January 20, 1998
Assignee:
Pharmacia & Upjohn Aktiebolag
Inventors:
Peter David Gluckman, David James Mellor
Abstract: The present invention provides the technique for isolating the toxin of the Sarcocystis protozoa, which may be later used in the production of specific antibodies against the sarcocystine responsible for the symptoms of sarcocystosis. The technique of the invention consists of separating the blood serum of an infected animal followed by dialysis thereof and finally the sample is dried. The technique is more effective when heart muscle material from an intermediate host with Sarcocystis cysts is used to contaminate a carnivorous mammal final host.
Abstract: Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
January 6, 1998
Assignee:
Applied Research Systems ARS Holding N.V.
Abstract: A pharmaceutical formulation comprising a growth hormone and Leu-His-Leu as additive or buffering substance shows a very high stability against deamidation, oxidation and cleavage of peptide bonds. The stability of the product allows for the storing and shipment thereof in a lyophilized state or in the form of a dissolved or re-dissolved formulation at ambient temperature.
Type:
Grant
Filed:
January 13, 1995
Date of Patent:
January 6, 1998
Assignee:
Novo Nordisk A/S
Inventors:
Thorkild Christensen, Per Balschmidt, Hans Holmegaard S.o slashed.rensen, Ole Hvilsted Olsen, Lars Thim
Abstract: Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, particularly in the anterior chamber of the eye. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
Abstract: A method of enhancing the survival of neuronal cells in a mammal, the cells being at risk of dying, the method comprising administering to the mammal an effective amount of at least one of the following substances: IGF-I; a functional derivative of IGF-I; IGF-II; a functional derivative of IGF-II; IGF-III; or a functional derivative of IGF-III.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
December 30, 1997
Assignee:
Cephalon, Inc.
Inventors:
Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Nicola Neff, Mohamed Iqbal
Abstract: A preventive for circulatory diseases which can prevent the onset of circulatory diseases, particularly cerebral stroke, without causing adverse effects such as blood-pressure fluctuation. The preventive contains as the active ingredient a low-molecular-weight peptide fraction prepared by the trypsinization of casein followed by partial purification.